AstraZeneca Plc recently unveiled groundbreaking findings from the DUO-E Phase 3 trial, showcasing the robust clinical benefit of combining Imfinzi and Lynparza in treating advanced or recurrent endometrial cancer.
Delving into the data, the results illuminated a significant enhancement in crucial secondary efficacy measures, particularly in the subset of patients with mismatch repair proficient (pMMR) endometrial cancer when compared to chemotherapy alone.
A meticulous post-hoc subgroup analysis, based on the mismatch repair (MMR) status, underscored compelling outcomes. Notably, patients in the Lynparza and Imfinzi arm exhibited a remarkable 18.7-month median duration of response – more than double that of the control arm at 7.6 months.
Further secondary endpoints reinforced the trend for pMMR patients treated with Lynparza and Imfinzi, evidencing a 32% decrease in the risk of second progression or death (PFS2) in the combination group versus the control arm (median not reached versus 19.5 months), alongside improvements in time to initial and subsequent treatments.
The study also showcased consistent benefits of Imfinzi plus chemotherapy followed by Imfinzi monotherapy irrespective of MMR status, with notable advantages observed in patients with mismatch repair deficient (dMMR) disease across all secondary endpoints. This group saw an impressive objective response rate (ORR) at 71.4% and a median duration of response not reached, compared to 40.5% ORR and 10.5 months of duration in the control arm.
Across the overall trial population, the Lynparza and Imfinzi arm displayed extended ORR and duration of response, as well as consistently improved secondary endpoints encompassing overall survival (OS), time to initial subsequent therapy, PFS2, and time to second subsequent treatment.
In a parallel move, AstraZeneca announced that starting June 1, 2024, eligible patients can access all AstraZeneca U.S. inhaled respiratory medicines for a nominal fee of no more than $35 per month, covering popular products like Airsupra, Bevespi Aerosphere, Breztri Aerosphere, and Symbicort.
Price Action: AZN shares are down 0.24% at $66.15 as of the latest update on Monday.
This illustration of a Pharma lab worker was masterfully crafted with MidJourney.
